Mechanism of Action
12.1 Mechanism of Action Tenofovir alafenamide is an antiviral drug against the hepatitis B virus [see ] . 12.2 Pharmacodynamics Cardiac Electrophysiology In a thorough QT/QTc study in 48 healthy subjects, tenofovir alafenamide at the recommended dose or at a dose 5 times the recommended dose did…
Clinical Trials (5)
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Loss of Exclusivity
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8754065 | Aug 15, 2032 | SubstanceProduct | U-3880 |
| 9296769 | Aug 15, 2032 | SubstanceProduct | U-999 |
| 8754065*PED | Feb 15, 2033 | — | |
| 9296769*PED | Feb 15, 2033 | — |